Phase 3 Clinical Trials With Primary Completion Dates in October 2019

This is a list of Phase 3 trials with primary completion dates in October 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
BYSI BeyondSpring, Inc. 2019-10-01 Phase 3 NCT02504489 Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC
CPRX Catalyst Pharmaceuticals, Inc. 2019-10-01 Phase 3 NCT03304054 Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
FOLD Amicus Therapeutics, Inc. 2019-10-01 Phase 3 NCT02194985 Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
GBT Global Blood Therapeutics, Inc. 2019-10-01 Phase 3 NCT03036813 Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)
ITRM Iterum Therapeutics plc 2019-10-01 Phase 3 NCT03358576 Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)
ITRM Iterum Therapeutics plc 2019-10-01 Phase 3 NCT03357614 Sulopenem Followed by Sulopenem-etzadroxil/Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults
ITRM Iterum Therapeutics plc 2019-10-01 Phase 3 NCT03354598 Oral Sulopenem-etzadroxil/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women
SNY Sanofi 2019-10-01 Phase 3 NCT03965962 Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults
SNY Sanofi 2019-10-01 Phase 3 NCT02992418 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects
SUPN Supernus Pharmaceuticals, Inc. 2019-10-01 Phase 3 NCT02618408 Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
ZLAB Zai Lab Limited 2019-10-01 Phase 3 NCT03516084 A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer